The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Metabolism Drugs Market Research Report 2024

Global Metabolism Drugs Market Research Report 2024

Publishing Date : Jan, 2024

License Type :
 

Report Code : 1410850

No of Pages : 88

Synopsis

Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.

The global Metabolism Drugs market was valued at US$ 16200 million in 2023 and is anticipated to reach US$ 23350 million by 2030, witnessing a CAGR of 5.3% during the forecast period 2024-2030.

USA is the largest supplier of Metabolism Drugs, with production revenue market share over 43%, while the sales market share is 40%. Europe, following USA, takes production revenue market share of 35% and the sales market share over 23%. That is to say, there are a large number of exports in Europe. Japan is an important market of Drugs for Metabolism Drugs in Asia, accounting for 9% production revenue market share and 10% sales revenue market share of global market.

Players with high-quality products are Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca and Beohrigher Ingelheim, with about 70% market shares.

This report aims to provide a comprehensive presentation of the global market for Metabolism Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolism Drugs.

Report Scope

The Metabolism Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metabolism Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Metabolism Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

By Company

  • Merck
  • Novartis
  • Takeda Pharmaceutical
  • Astra Zeneca
  • Beohrigher Ingelheim
  • KOWA
  • Kythera
  • Fuji yakuhin
  • LG Life Science
  • Metsubishi Tanabe Pharma

Segment by Type

  • Glycogen Metabolism Disease Drug
  • Lipid Metabolism Disease Drug
  • Amino Acid Metabolism Drug
  • Other

Segment by Application

  • Hospital
  • Retail Pharmacy

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Metabolism Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Metabolism Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Metabolism Drugs Market Overview
1.1 Product Overview and Scope of Metabolism Drugs
1.2 Metabolism Drugs Segment by Type
1.2.1 Global Metabolism Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Glycogen Metabolism Disease Drug
1.2.3 Lipid Metabolism Disease Drug
1.2.4 Amino Acid Metabolism Drug
1.2.5 Other
1.3 Metabolism Drugs Segment by Application
1.3.1 Global Metabolism Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.4 Global Metabolism Drugs Market Size Estimates and Forecasts
1.4.1 Global Metabolism Drugs Revenue 2019-2030
1.4.2 Global Metabolism Drugs Sales 2019-2030
1.4.3 Global Metabolism Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Metabolism Drugs Market Competition by Manufacturers
2.1 Global Metabolism Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Metabolism Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Metabolism Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Metabolism Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Metabolism Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Metabolism Drugs, Product Type & Application
2.7 Metabolism Drugs Market Competitive Situation and Trends
2.7.1 Metabolism Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Metabolism Drugs Players Market Share by Revenue
2.7.3 Global Metabolism Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Metabolism Drugs Retrospective Market Scenario by Region
3.1 Global Metabolism Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Metabolism Drugs Global Metabolism Drugs Sales by Region: 2019-2030
3.2.1 Global Metabolism Drugs Sales by Region: 2019-2024
3.2.2 Global Metabolism Drugs Sales by Region: 2025-2030
3.3 Global Metabolism Drugs Global Metabolism Drugs Revenue by Region: 2019-2030
3.3.1 Global Metabolism Drugs Revenue by Region: 2019-2024
3.3.2 Global Metabolism Drugs Revenue by Region: 2025-2030
3.4 North America Metabolism Drugs Market Facts & Figures by Country
3.4.1 North America Metabolism Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Metabolism Drugs Sales by Country (2019-2030)
3.4.3 North America Metabolism Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Metabolism Drugs Market Facts & Figures by Country
3.5.1 Europe Metabolism Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Metabolism Drugs Sales by Country (2019-2030)
3.5.3 Europe Metabolism Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Metabolism Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Metabolism Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Metabolism Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Metabolism Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Metabolism Drugs Market Facts & Figures by Country
3.7.1 Latin America Metabolism Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Metabolism Drugs Sales by Country (2019-2030)
3.7.3 Latin America Metabolism Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Metabolism Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Metabolism Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Metabolism Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Metabolism Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Metabolism Drugs Sales by Type (2019-2030)
4.1.1 Global Metabolism Drugs Sales by Type (2019-2024)
4.1.2 Global Metabolism Drugs Sales by Type (2025-2030)
4.1.3 Global Metabolism Drugs Sales Market Share by Type (2019-2030)
4.2 Global Metabolism Drugs Revenue by Type (2019-2030)
4.2.1 Global Metabolism Drugs Revenue by Type (2019-2024)
4.2.2 Global Metabolism Drugs Revenue by Type (2025-2030)
4.2.3 Global Metabolism Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Metabolism Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Metabolism Drugs Sales by Application (2019-2030)
5.1.1 Global Metabolism Drugs Sales by Application (2019-2024)
5.1.2 Global Metabolism Drugs Sales by Application (2025-2030)
5.1.3 Global Metabolism Drugs Sales Market Share by Application (2019-2030)
5.2 Global Metabolism Drugs Revenue by Application (2019-2030)
5.2.1 Global Metabolism Drugs Revenue by Application (2019-2024)
5.2.2 Global Metabolism Drugs Revenue by Application (2025-2030)
5.2.3 Global Metabolism Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Metabolism Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Metabolism Drugs Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis Metabolism Drugs Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Takeda Pharmaceutical
6.3.1 Takeda Pharmaceutical Corporation Information
6.3.2 Takeda Pharmaceutical Description and Business Overview
6.3.3 Takeda Pharmaceutical Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Takeda Pharmaceutical Metabolism Drugs Product Portfolio
6.3.5 Takeda Pharmaceutical Recent Developments/Updates
6.4 Astra Zeneca
6.4.1 Astra Zeneca Corporation Information
6.4.2 Astra Zeneca Description and Business Overview
6.4.3 Astra Zeneca Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Astra Zeneca Metabolism Drugs Product Portfolio
6.4.5 Astra Zeneca Recent Developments/Updates
6.5 Beohrigher Ingelheim
6.5.1 Beohrigher Ingelheim Corporation Information
6.5.2 Beohrigher Ingelheim Description and Business Overview
6.5.3 Beohrigher Ingelheim Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Beohrigher Ingelheim Metabolism Drugs Product Portfolio
6.5.5 Beohrigher Ingelheim Recent Developments/Updates
6.6 KOWA
6.6.1 KOWA Corporation Information
6.6.2 KOWA Description and Business Overview
6.6.3 KOWA Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 KOWA Metabolism Drugs Product Portfolio
6.6.5 KOWA Recent Developments/Updates
6.7 Kythera
6.6.1 Kythera Corporation Information
6.6.2 Kythera Description and Business Overview
6.6.3 Kythera Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kythera Metabolism Drugs Product Portfolio
6.7.5 Kythera Recent Developments/Updates
6.8 Fuji yakuhin
6.8.1 Fuji yakuhin Corporation Information
6.8.2 Fuji yakuhin Description and Business Overview
6.8.3 Fuji yakuhin Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Fuji yakuhin Metabolism Drugs Product Portfolio
6.8.5 Fuji yakuhin Recent Developments/Updates
6.9 LG Life Science
6.9.1 LG Life Science Corporation Information
6.9.2 LG Life Science Description and Business Overview
6.9.3 LG Life Science Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 LG Life Science Metabolism Drugs Product Portfolio
6.9.5 LG Life Science Recent Developments/Updates
6.10 Metsubishi Tanabe Pharma
6.10.1 Metsubishi Tanabe Pharma Corporation Information
6.10.2 Metsubishi Tanabe Pharma Description and Business Overview
6.10.3 Metsubishi Tanabe Pharma Metabolism Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Metsubishi Tanabe Pharma Metabolism Drugs Product Portfolio
6.10.5 Metsubishi Tanabe Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Metabolism Drugs Industry Chain Analysis
7.2 Metabolism Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Metabolism Drugs Production Mode & Process
7.4 Metabolism Drugs Sales and Marketing
7.4.1 Metabolism Drugs Sales Channels
7.4.2 Metabolism Drugs Distributors
7.5 Metabolism Drugs Customers
8 Metabolism Drugs Market Dynamics
8.1 Metabolism Drugs Industry Trends
8.2 Metabolism Drugs Market Drivers
8.3 Metabolism Drugs Market Challenges
8.4 Metabolism Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’